Astrazeneca PLC 6-K, filed Jun 28, 2021
Astrazeneca PLC (AZN)
6-K
2021-06-28
For: 2021-06-28
View Original
Added on
July 04, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on June 28, 2021.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of June 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1. Nirsevimab
PhII/III trial confirms safety profile
28 June 2021 07:00 BST
Nirsevimab MEDLEY Phase II/III trial demonstrated favourable
safety
and tolerability profile in infants at high risk of
RSV
Nirsevimab is being developed as a passive immunisation against RSV
for all infants
The MEDLEY Phase II/III trial evaluated the safety and tolerability
of nirsevimab compared to Synagis (palivizumab) when given to infants at high
risk of respiratory syncytial virus (RSV) entering their first RSV
season.1
The trial assessed the safety of nirsevimab in infants with chronic
lung disease (CLD), congenital heart disease (CHD) and/or
prematurity. Occurrence of treatment emergent adverse events
(TEAEs) or treatment emergent serious adverse events (TESAEs) were
similar between groups.1
Nirsevimab is a long-acting antibody, using AstraZeneca's
proprietary YTE technology, being developed by AstraZeneca and
Sanofi with the potential to provide immunity directly to all
infants and offer immediate protection against RSV through the
entire season with a single dose.
Dr Joseph Domachowske, Professor of Pediatrics and Professor of
Microbiology and Immunology at the State University of New York,
Upstate Medical Center, Syracuse, NY and MEDLEY trial primary
investigator, said: "These data for nirsevimab are important as
they show a safety and tolerability profile comparable to the only
available preventative option against lower respiratory tract
infections caused by respiratory syncytial virus for preterm
infants and those with health conditions. Given the typical respiratory
syncytial virus season lasts nearly five months, there is a
potential advantage to providing a preventative option that could
help protect all infants with one dose for the entire
season."
Mene Pangalos, Executive Vice President, BioPharmaceuticals
R&D, said: "Respiratory syncytial virus is the leading cause of
hospitalisations in infants. These results, combined with the
recent positive efficacy outcome of our MELODY Phase III trial and
our Phase IIb data, contribute to the body of evidence
demonstrating nirsevimab's potential to protect all infants against
respiratory syncytial virus with one dose. We look forward to
sharing the results with regulators."
Jean-François Toussaint, Global Head of Research and
Development, Sanofi Pasteur: "Respiratory syncytial virus is the
major remaining paediatric infectious disease with no preventative
option available to all infants. We believe nirsevimab has the
potential to become an important and innovative routine
immunisation for all infants - those born prematurely or at term,
healthy or with health conditions."
Full results from the MEDLEY trial will be presented at a
forthcoming medical meeting. The trial is ongoing to collect
additional safety data.
Nirsevimab is also being evaluated in the MELODY Phase III trial,
which met its primary
endpoint of a
statistically significant reduction in the incidence of medically
attended LRTI caused by RSV, compared to placebo, in healthy late
preterm and term infants during their first RSV
season. MEDLEY, MELODY and the Phase IIb
trial will form the basis
of AstraZeneca's regulatory submissions planned from the first half
of 2022.
Nirsevimab has been granted breakthrough designation by three major
regulatory agencies around the world. These include Breakthrough
Therapy Designation by The China Center for Drug Evaluation under
the National Medical Products
Administration; Breakthrough Therapy
Designation from the US
Food and Drug Administration; and access granted to the European
Medicines Agency PRIority MEdicines
(PRIME) scheme.
RSV
RSV is a common, contagious pathogen that causes seasonal epidemics
of lower respiratory tract infections (LRTI), including
bronchiolitis and pneumonia.2-4 It
is the leading cause of hospitalisations in infants
worldwide.4 Currently, Synagis is
the only approved option for the prevention of serious LRTI caused
by RSV in preterm infants and infants at high risk and requires up
to five injections to cover a typical RSV
season.5 Globally,
in 2015, there were approximately 30 million cases of acute lower
respiratory infections leading to more than three million
hospitalisations, and it was estimated that there were 60,000
in-hospital deaths of children younger than five
years.4,6 Most
hospitalisations for RSV occur in otherwise healthy infants born at
term.7-11 Medically
attended LRTIs are associated with increased costs to the
healthcare system.12
MEDLEY
MEDLEY is a Phase II/III, randomised,
double-blind, Synagis-controlled trial with the primary objective of
assessing safety and tolerability for nirsevimab in preterm infants
and infants at high risk eligible to
receive Synagis. Between July 2019 and May 2021 approximately 925
infants entering their first RSV season were dosed with either
nirsevimab or Synagis. Safety is assessed by monitoring the occurrence
of TEAEs and TESAEs through 360 days post-dose. High-risk infants
are defined as infants 35 weeks 0 days or lesser gestational age
without CLD/CHD, or infants with CLD of prematurity or
hemodynamically significant CHD.1
The evaluation of the safety and tolerability of nirsevimab in the
MEDLEY trial was carried out earlier than anticipated. A primary
analysis was conducted to allow earlier assessment of nirsevimab's
safety and tolerability versus Synagis based on a sufficient number of infants
being enrolled and followed through their first RSV
season.
MELODY
MELODY is a randomised, placebo-controlled Phase III trial
conducted across at least 21 countries designed to determine the
incidence of medically attended LRTI due to RSV confirmed by
reverse transcriptase polymerase chain reaction (RT-PCR) testing
through 150 days after dosing, versus placebo, in healthy infants
entering their first RSV season. Healthy late preterm and term
infants born at 35 weeks 0 days or greater gestational age were
randomised (2:1) to receive a single 50mg (in infants weighing
<5kg) or 100mg (in infants weighing >5kg) intramuscular
injection of nirsevimab or placebo. Between July 2019 and February
2021 approximately 1,500 infants were dosed with either nirsevimab
or placebo at the RSV season start.13 An
additional 1,500 infants will be enrolled in the Northern and
Southern Hemispheres to complete the safety
evaluation.
Nirsevimab
Nirsevimab is a long-acting antibody being developed as a passive
immunisation for the prevention of LRTI caused by RSV. It is being
developed for use with all infants, in comparison to the current
standard of care, Synagis, which is limited to infants at high
risk.5,
14,15 Due to its extended
half-life technology, nirsevimab may only require one dose during a
typical five-month RSV season.15 The
current anti-RSV antibody, AstraZeneca's Synagis, is limited to high-risk infants and provides
one-month protection, requiring five injections to cover an RSV
season.5
Nirsevimab is a passive immunisation, designed to provide RSV
protection to all infants, whereby an antibody is given directly to
an infant to help prevent RSV, unlike active immunisation, where
the infants' own immune system is activated to prevent or fight
infection.16 Passive
immunisation could offer immediate protection unlike active
immunisation, which can take weeks to develop
protection.16
In March 2017, AstraZeneca and Sanofi announced
an agreement to
develop and commercialise nirsevimab. Under the terms of the
agreement, AstraZeneca leads all development and manufacturing
activities and Sanofi will lead commercialisation activities and
record revenues. Under the terms of the global agreement, Sanofi
made an upfront payment of €120m, has paid a development
milestone of €30m and will pay up to a further €465m
upon achievement of certain development and sales-related
milestones. The two companies share all costs and profits. Revenue
from the agreement is reported as Collaboration Revenue in the
Company's financial statements.
Related, in November 2018, AstraZeneca divested US commercial
rights for Synagis to Swedish Orphan Biovitrum AB (publ) (Sobi)
in addition to the right to participate in payments that may be
received by AstraZeneca from the US profits or losses for
nirsevimab. Under the agreement,
AstraZeneca received upfront consideration of $1.5bn, consisting of
$1.0bn in cash and $500m in ordinary shares of Sobi upon
completion, and will have received a total of $60m in
non-contingent payments for nirsevimab during 2019-2021.
AstraZeneca will also receive up to $470m in sales-related
payments for Synagis,
a $175m milestone following the submission of the Biologics License
Application (BLA) for nirsevimab and potential net payments of
approximately $110m on achievement of other nirsevimab profit and
development-related milestones. Upon payment of the $175m milestone
on BLA submission, Sobi's ongoing participation will amount to
AstraZeneca's full share of profits or losses under the agreement
with Sanofi for nirsevimab in the US. AstraZeneca will continue to
manufacture and supply nirsevimab globally and is entitled to an
additional royalty from Sobi if profits from nirsevimab in the US
exceed a pre-specified level.
AstraZeneca in Respiratory & Immunology
Respiratory & Immunology, part of BioPharmaceuticals, is one of
AstraZeneca's three disease areas and is a key growth driver for
the Company.
AstraZeneca is an established leader in respiratory care with a
50-year heritage. The Company aims to transform the treatment of
asthma and COPD by focusing on earlier biology-led treatment,
eliminating preventable asthma attacks, and removing COPD as a
top-three leading cause of death. The Company's early respiratory
research is focused on emerging science involving immune
mechanisms, lung damage and abnormal cell-repair processes in
disease and neuronal dysfunction.
With common pathways and underlying disease drivers across
respiratory and immunology, AstraZeneca is following the science
from chronic lung diseases to immunology-driven disease areas. The
Company's growing presence in immunology is focused on five mid- to
late-stage franchises with multi-disease potential, in areas
including rheumatology (including systemic lupus erythematosus),
dermatology, gastroenterology, and systemic eosinophilic-driven
diseases. AstraZeneca's ambition in Respiratory & Immunology is
to achieve disease modification and durable remission for millions
of patients worldwide.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology and BioPharmaceuticals, including Cardiovascular, Renal
& Metabolism, and Respiratory & Immunology. Based in
Cambridge, UK, AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1. Clinicaltrials.gov. A Study to Evaluate the Safety of MEDI8897
for the Prevention of Medically Attended Respiratory Syncytial
Virus (RSV) Lower Respiratory Track Infection (LRTI) in High-risk
Children. https://clinicaltrials.gov/ct2/show/NCT03959488. Accessed
June 2021.
2. Piedimonte G, Perez MK. Pediatr Rev.
2014;35(12):519-53
3. Oymar K et al. Scand J Trauma Resusc Emerg
Med.
2014;22:23
4. Shi T, et al. Global, regional, and national disease
burden estimates of acute lower respiratory infections due to
respiratory syncytial virus in young children in 2015: a systematic
review and modelling study. Lancet 2017; 390: 946-58.
5. Synagis (palivizumab) injection prescribing
information. Available at: https://www.synagis.com/synagis.pdf.
Accessed June 2021.
6. Oxford Vaccines Group. What is RSV?
https://vk.ovg.ox.ac.uk/vk/rsv. Accessed April 2021
7. Hall CB, et al. Respiratory syncytial virus-associated
hospitalizations among children less than 24 months of
age. Pediatrics. 2013;132:e341-e348.
8. Rha B, et al. Respiratory Syncytial Virus-Associated
Hospitalizations Among Young Children:
2015-2016. Pediatrics. 2020;146:e20193611.
9. Arriola CS, et al. Estimated Burden of Community-Onset
Respiratory Syncytial Virus-Associated Hospitalizations Among
Children Aged <2 Years in the United States,
2014-15. J Pediatric Infect Dis
Soc. 2020;9:587-595
10. Krilov LR, et al. Impact of the 2014 American Academy
of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and
Cost of Respiratory Syncytial Virus Hospitalizations among Preterm
Infants. Am J
Perinatol. 2020;37:174-183.
11. Scheltema NM, et al. Global respiratory syncytial
virus-associated mortality in young children (RSV GOLD): a
retrospective case series. Lancet Glob
Health. 2017;5:e984-9.
12. Zhang S et al. J Infect
Dis. 2020. doi:
10.1093/infdis/jiz683
13. Clinicaltrials.gov. A Study to Evaluate the Safety and Efficacy
of MEDI8897 for the Prevention of Medically Attended RSV LRTI in
Healthy Late Preterm and Term Infants (MELODY).
https://clinicaltrials.gov/ct2/show/NCT03979313. Accessed June
2021.
14. Villafana T, et al. Passive and active immunization
against respiratory syncytial virus for the young and
old. Expert Rev
Vaccines.
2017;16:1-39.
15. Zhu Q, et al. A highly potent extended half-life
antibody as a potential RSV vaccine surrogate for all
infants. Sci Transl
Med. 2017;9:pii:
eaaj1928
16. Centers for Disease Control and Prevention. Vaccines &
Immunizations. August 18, 2017.
https://www.cdc.gov/vaccines/vac-gen/immunity-types.htm. Accessed
June 2021.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
28 June
2021
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|